Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal
EMAGine’s Chief Scientific Officer, Professor Farhad Hafezi of the ELZA Institute in Zurich, Switzerland, has prepared a presentation that provides a comprehensive overview of how oxygen concentration is at the center of all these decisions.
This month, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
Speaker: Prof. Farhad Hafezi, ELZA Institute
Meeting: AOPA: Association des ophtalmologues privés algériens
Date: March 26, 2021
Language: Français
Summary: Le Pr Hafezi de l’institut ELZA en Suisse parle du cross-linking dans les cornées ultrafines. Nouveau protocôle publié dans le prestigieux “American Journal of Ophthalmology” et implémenté dans la machine C-eye.
Short introduction video to the C-eye device and Ribo-Ker riboflavin solution.
Speaker: Prof. Farhad Hafezi, ELZA Institute
Meeting: Hellenic Society for Intraocular Implants and Refractive Surgery (HSIOIRS)
Date: March 2021
Language: English
Summary: Prof. Hafez gives on overview about the current state of CXL technology at the annual Hellenic HSOIRS meeting 2021
Speaker: Prof. Farhad Hafezi, ELZA Institute
Meeting: CSO Italia Webinar. Innovative Ophthalmology
Date: February 2021
Language: English
Summary: Prof. Farhad Hafezi from the ELZA Institute in Switzerland explains corneal cross-linking for keratoconus and keratitis at the slit lamp.
Speaker: Prof. Farhad Hafezi. ELZA Institute.
Meeting: CSO Italia webinar on emerging new technologies
Date: February 2021
Language: English
Summary: International webinar, organized by CSO Italia, to highlight new developments in the field of anterior segment diagnostics and treatment.
Speaker: Prof. Farhad Hafezi, ELZA Institute
Meeting: Al Qassimi International Conference, UAE
Date: February 2021
Language: English
Summary: Keratoglobus was the only remaining ectatic corneal disease that could not be treated – until now: the sub400m protocol allows for cross-linking in ultrathin corneas.
